Organogenesis Holdings Inc. (NASDAQ:ORGO) Short Interest Up 29.1% in December

Organogenesis Holdings Inc. (NASDAQ:ORGO) was the target of a large increase in short interest in December. As of December 15th, there was short interest totalling 11,000,000 shares, an increase of 29.1% from the November 30th total of 8,520,000 shares. Approximately 16.3% of the shares of the company are sold short. Based on an average daily trading volume, of 690,900 shares, the short-interest ratio is currently 15.9 days.

Insider Transactions at Organogenesis

In other news, CEO Gary S. Gillheeney sold 55,615 shares of the company’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $3.36, for a total transaction of $186,866.40. Following the transaction, the chief executive officer now directly owns 3,044,779 shares of the company’s stock, valued at $10,230,457.44. This represents a 1.79 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In the last three months, insiders sold 278,116 shares of company stock valued at $991,190. Corporate insiders own 36.90% of the company’s stock.

Institutional Trading of Organogenesis

A number of institutional investors have recently bought and sold shares of ORGO. Captrust Financial Advisors purchased a new position in shares of Organogenesis in the third quarter valued at $36,000. Delap Wealth Advisory LLC acquired a new stake in Organogenesis in the 2nd quarter valued at about $40,000. Intech Investment Management LLC purchased a new position in Organogenesis during the 3rd quarter valued at about $43,000. Allspring Global Investments Holdings LLC raised its position in Organogenesis by 4,989.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 15,677 shares of the company’s stock worth $44,000 after acquiring an additional 15,369 shares during the last quarter. Finally, Pallas Capital Advisors LLC raised its position in Organogenesis by 70.8% during the third quarter. Pallas Capital Advisors LLC now owns 21,823 shares of the company’s stock worth $63,000 after acquiring an additional 9,048 shares during the last quarter. 49.57% of the stock is currently owned by hedge funds and other institutional investors.

Organogenesis Stock Down 0.9 %

ORGO stock opened at $3.16 on Tuesday. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The company’s 50-day moving average price is $3.46 and its 200 day moving average price is $3.04. Organogenesis has a 52 week low of $2.16 and a 52 week high of $4.70. The company has a market cap of $397.29 million, a P/E ratio of -52.67 and a beta of 1.73.

Organogenesis (NASDAQ:ORGO) last posted its quarterly earnings results on Tuesday, November 12th. The company reported $0.09 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.11. The company had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. Organogenesis had a negative net margin of 1.62% and a negative return on equity of 2.69%. During the same period last year, the firm earned $0.02 EPS. On average, research analysts expect that Organogenesis will post -0.07 earnings per share for the current fiscal year.

Organogenesis Company Profile

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.